Drug Profile

NTM 006

Alternative Names: JNJ 10450232; JNJ-232; NTM-006

Latest Information Update: 28 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen
Developer McNeil Consumer Pharmaceuticals; Neumentum
Class Analgesics; Non-opioid analgesics
Mechanism of Action Adenosine A3 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Postoperative pain
No development reported Neuropathic pain; Pain

Most Recent Events

28 Nov 2024 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
28 Nov 2024 No recent reports of development identified for preclinical development in Pain in USA (PO)
28 Nov 2022 Phase II development is still ongoing for Postoperative pain in USA (PO) (Neumentum pipeline, November 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com